Lilly, AlzeCure ink Alzheimer’s drug deal (LLY:NYSE)

Eli Lilly (LLY) stock is in focus as Swedish biotech AlzeCure partners with the company to develop an Alzheimer’s therapy in a deal worth more than $1B. Read more here.

Read on WOBR AI →